CAMBRIDGE, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will present
at two healthcare conferences in March 2004.
TKT will participate at Lehman Brothers 7th Annual Global Healthcare
Conference in Miami, Florida March 3-5, 2004. Michael J. Astrue, President
and Chief Executive Officer will present an overview of TKT's business
activities at 10:15 a.m. Eastern Time on Wednesday, March 3, 2004.
TKT will also participate at SG Cowen Securities 24th Annual Healthcare
Conference in Boston, Massachusetts on March 8-11, 2004. A presentation of
TKT's business activities will be given by David D. Pendergast, Ph.D.,
Executive Vice President and Chief Operating Officer at 1:15 p.m. and 2:15
p.m. Eastern Time on Wednesday, March 10, 2004.
The live audio webcast of these presentations will be available at
http://www.tktx.com in TKT's Investor Information website under the Events category.
A replay of both presentations will be available for approximately two weeks
following the live audio webcasts.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company committed to
developing treatments for rare diseases caused by protein deficiencies with a
core focus on lysosomal storage diseases. The company markets one product,
Replagal(TM), an enzyme replacement therapy for Fabry disease in Europe and
other countries and is developing treatments for Hunter syndrome and Gaucher
disease. TKT's research pipeline focuses on rare diseases where a significant
unmet medical need exists. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
Latin America. Additional information about TKT is available on the company's
website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist of Transkaryotic Therapies, Inc., +1-617-349-0205
|
